Jubilant Pharmova First Quarter Net Profit Up 82.43% to Rs160.56cr as Pharmaceutical EBITDA Grows 170% YoY


Jubilant Pharmova reported a 41.40% increase in total revenue for the June 21 quarter on a consolidated basis to Rs1,634.65cr. On a sequential basis, revenue increased 3.47% from revenue of Rs1,579.78cr on March 21. COVID 2.0 had a limited impact on revenue for the June 21 quarter.

The pharmaceuticals vertical grew 40% year-on-year while contract research and development (CDMO) also hit the streets with 50% year-on-year growth. The life sciences segment has been separated and presented as part of the discontinued operations.

Net profit for the June 21 quarter increased 82.43% to Rs160.56cr on an annual basis, but on a sequential basis the PAT was down -24.94% due to the impact of COVID 2.0. The increase in EBITDA stems from the pharmaceutical business which saw EBITDA increase by almost 170% year-on-year.

CDMO’s EBITDA also more than doubled year-on-year. Net margins at 9.82% for the June 21 quarter are significantly higher than 7.61% in the June 20 quarter but below 13.54% in the sequential March 21 quarter. However, the previous figures include discontinued operations.

June 21 financial highlights compared year-over-year and sequentially

Jubilant Pharmova
Rs in crore June-21 June 20 YEAR Mar-21 QOQ
Total income (Rs cr) ₹ 1,634.65 1,156.07 41.40% ₹ 1,579.78 3.47%
Net profit (Rs cr) 160.56 88.01 82.43% 213 213.90 -24.94%
Diluted EPS (Rs) 10.09 5.53 13.43
Net margins 9.82% 7.61% 13.54%

Related story

Related Tags:


Leave A Reply